Targeted quantitative analysis of superoxide dismutase 1 in cisplatin-sensitive and cisplatin-resistant human ovarian cancer cells

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 878, Issue 7-8, 2010, Pages 700-704

  Kim, Jong Won ^a   Nie, Bei ^a   Sahm, Heather ^a   Brown, Dawn P G ^a   Tegeler, Tony ^b   You, Jin Sam ^b   Wang, Mu ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Monarch LifeSciences   (United States)

Author keywords

Cisplatin drug resistance; Mass spectrometry; Ovarian cancer; Selected reaction monitoring; Superoxide dismutase 1

Indexed keywords

CIS-PLATIN; DRUG RESISTANCE; OVARIAN CANCERS; SELECTED-REACTION-MONITORING; SUPER OXIDE DISMUTASE;

CELL CULTURE; CELLS; GENE EXPRESSION; MASS SPECTROMETERS; MASS SPECTROMETRY; MONITORING; OXYGEN; PEPTIDES;

PLATINUM COMPOUNDS;

CISPLATIN; COPPER ZINC SUPEROXIDE DISMUTASE;

ARTICLE; CANCER CELL; HUMAN; HUMAN CELL; MASS SPECTROMETRY; OVARY CANCER; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS;

CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; ENZYME STABILITY; FEMALE; HUMANS; MASS SPECTROMETRY; OVARIAN NEOPLASMS; PEPTIDE FRAGMENTS; PROTEOMICS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SUPEROXIDE DISMUTASE;

EID: 76549089792     PISSN: 15700232     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchromb.2010.01.013     Document Type: Article

References (24)

1. Landis S.H., Murray T., Bolden S., and Wingo P.A. CA. Cancer J. Clin. 49 (1999) 8
2. Markman M. Ther. Clin. Risk Manage. 5 (2009) 161
3. Auersperg N., Edelson M.I., Mok S.C., Johnson S.W., and Hamilton T.C. Semin. Oncol. 25 (1998) 281
4. Johnson S.W., Laub P.B., Beesley J.S., Ozols R.F., and Hamilton T.C. Cancer Res. 57 (1997) 850
5. Zamble D.B., and Lippard S.J. Trends Biochem. Sci. 20 (1995) 435
6. Fitzpatrick D.P.G., You J., Bemis K.G., Wery J.-P., Ludwig J.R., and Wang M. Proteomics - Clin Appl. 1 (2007) 246
7. Noor R., Mittal S., and Iqbal J. Med. Sci. Monit. 8 (2002) RA210
8. Rao A.K., Ziegler Y.S., McLeod I.X., Yates J.R., and Nardulli A.M. Mol. Endocrinol. 22 (2008) 1113
9. Kanekura K., Hashimoto Y., Kita Y., Sasabe J., Aiso S., Nishimoto I., and Matsuoka M. J. Biol. Chem. 280 (2005) 4532
10. Tanaka M., Mokhtari G.K., Terry R.D., Balsam L.B., Lee K.H., Kofidis T., Tsao P.S., and Robbins R.C. Circulation 110 (2004) 11200
11. Plasencia C., Martinez-Balibrea E., Martinez-Cardus A., Quinn D.I., Abad A., and Neamati N. Int. J. Oncol. 29 (2006) 225
12. Burnette W.N. Methods Mol. Biol. 536 (2009) 5
13. Yates J.R., Ruse C.I., and Nakorchevsky A. Annu. Rev. Biomed. Eng. 11 (2009) 49
14. Onorato J.M., Henion J.D., Lefebvre P.M., and Kiplinger J.P. Anal. Chem. 73 (2001) 119
15. Schiess R., Wollscheid B., and Aebersold R. Mol. Oncol. 3 (2009) 33
16. Katano K., Kondo A., Safaei R., Holzer A., Samimi G., Mishima M., Kuo Y.M., Rochdi M., and Howell S.B. Cancer Res. 62 (2002) 6559
17. Samimi G., Katano K., Holzer A.K., Safaei R., and Howell S.B. Mol. Pharmacol. 66 (2004) 25
18. Holzer A.K., Samimi G., Katano K., Naerdemann W., Lin X., Safaei R., and Howell S.B. Mol. Pharmacol. 66 (2004) 817
19. Holzer A.K., Katano K., Klomp L.W., and Howell S.B. Clin. Cancer Res. 10 (2004) 6744
20. Bradford M.M. Anal. Biochem. 72 (1976) 248
21. Sherman J., McKay M.J., Ashman K., and Molloy M.P. Proteomics 9 (2009) 1120
22. Duncan M.W., Yergey A.L., and Patterson S.D. Proteomics 9 (2009) 1124
23. Panchaud A., Scherl A., Shaffer S.A., von Haller P.D., Kulasekara H.D., Miller S.I., and Goodlett D.R. Anal. Chem. 81 (2009) 6481
24. Ahmed F.E. J. Sep. Sci. 32 (2009) 771